- Home
- BHE vs NRIX Comparison
BHE vs NRIX Comparison
Compare BHE & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BHE | NRIX |
|---|---|---|
| Founded | 1979 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BHE | NRIX |
|---|---|---|
| Price | $81.64 | $26.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $55.00 | $30.50 |
| AVG Volume (30 Days) | 318.5K | ★ 971.9K |
| Earning Date | 04-29-2026 | 04-08-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $2,659,108,000.00 | $76,987,000.00 |
| Revenue This Year | $7.03 | N/A |
| Revenue Next Year | $6.57 | $48.05 |
| P/E Ratio | $89.84 | ★ N/A |
| Revenue Growth | 0.11 | ★ 99.31 |
| 52 Week Low | $35.97 | $8.20 |
| 52 Week High | $100.41 | $28.00 |
Technical Indicators
Market Signals| Indicator | BHE | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 48.62 | 69.53 |
| Support Level | $79.59 | $14.63 |
| Resistance Level | $87.37 | N/A |
| Average True Range (ATR) | 4.13 | 1.07 |
| MACD | 0.27 | 0.20 |
| Stochastic Oscillator | 67.90 | 82.19 |
Price Performance
Historical ComparisonAbout BHE Benchmark Electronics Inc.
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia, and Europe, of which key revenue is derived from the Americas.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.